Why did Idorsia stock rise today?

The company reported strong 2025 results, with QUVIVIQ net sales at CHF 134 million, more than doubling year over year. Guidance for 2026 targets CHF 200 million in QUVIVIQ sales, and management highlighted upcoming catalysts. This combination of growth, discipline, and pipeline potential lifted sentiment and supported a positive move in Idorsia stock.

Is Idorsia profitable after the 2025 results?

No. Management indicated the loss narrowed thanks to focused spending and improving gross profit, but the company remains unprofitable. Investors should monitor quarterly operating expenses, gross margin, and cash burn. Sustained revenue growth and any partnership income will be key to moving Idorsia stock closer to breakeven over time.

What is Idorsia’s 2026 guidance for QUVIVIQ?

Management guided QUVIVIQ net sales to CHF 200 million in 2026, up from CHF 134 million delivered in 2025. Hitting this target depends on continued prescriber adoption, payer coverage, and patient retention. Progress against quarterly KPIs will shape market confidence and the next leg for Idorsia stock.

How risky is Idorsia stock now?

Risk remains meaningful. Cash per share is modest, leverage is elevated versus market cap, and profitability is not yet reached. Execution on sales and any partnership cash can ease financing needs. Volatility is moderate, so position sizing and risk controls are essential when trading or investing in Idorsia stock.

Global Market Insights

IDIA.SW Stock Today: 2025 Beat, QUVIVIQ Sales Double — February 27

ByDanny Kontos February 27, 2026February 27, 2026

Idorsia stock is in focus in Switzerland after a clear 2025 beat. QUVIVIQ net sales reached CHF 134 million, more than doubling year over year, while the company narrowed its loss and set 2026 guidance at CHF 200 million for QUVIVIQ. Shares on SIX, IDIA.SW, recently traded near CHF 3.95, up 5.33% on the day, with an intraday range of CHF 3.59 to CHF 4.15. We look at results, catalysts, valuation, and the technical setup relevant for Swiss investors today.